These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35586439)

  • 1. Indazole and Benzoisoxazole Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2022 May; 13(5):763-764. PubMed ID: 35586439
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2023 Aug; 14(8):1043-1044. PubMed ID: 37583831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jul; 14(7):891-892. PubMed ID: 37465297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biaryl Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2022 Feb; 13(2):158-159. PubMed ID: 35178168
    [No Abstract]   [Full Text] [Related]  

  • 5. Heterocyclic Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2021 Nov; 12(11):1641-1642. PubMed ID: 34795852
    [No Abstract]   [Full Text] [Related]  

  • 6. Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).
    Sabnis RW
    ACS Med Chem Lett; 2021 Feb; 12(2):170-171. PubMed ID: 33603957
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Cisar JS; Pietsch C; DeRatt LG; Jacoby E; Kazmi F; Keohane C; Legenski K; Matico R; Shaffer P; Simonnet Y; Tanner A; Wang CY; Wang W; Attar R; Edwards JP; Kuduk SD
    J Med Chem; 2022 Aug; 65(16):11241-11256. PubMed ID: 35925768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.
    Galati S; Sainas S; Giorgis M; Boschi D; Lolli ML; Ortore G; Poli G; Tuccinardi T
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
    Knecht W; Henseling J; Löffler M
    Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia.
    Houshmand M; Vitale N; Orso F; Cignetti A; Molineris I; Gaidano V; Sainas S; Giorgis M; Boschi D; Fava C; Passoni A; Gai M; Geuna M; Sora F; Iurlo A; Abruzzese E; Breccia M; Mulas O; Caocci G; Castagnetti F; Taverna D; Oliviero S; Pane F; Lolli ML; Circosta P; Saglio G
    Cell Death Dis; 2022 Jun; 13(6):576. PubMed ID: 35773274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
    Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y
    Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
    Zhang X; Hufnagel H; Hou C; Opas E; McKenney S; Crysler C; O'Neill J; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6042-8. PubMed ID: 21917454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
    Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F
    Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
    Kadir MFA; Othman S; Nellore K
    Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
    Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
    Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.
    Sainas S; Pippione AC; Lupino E; Giorgis M; Circosta P; Gaidano V; Goyal P; Bonanni D; Rolando B; Cignetti A; Ducime A; Andersson M; Järvå M; Friemann R; Piccinini M; Ramondetti C; Buccinnà B; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
    J Med Chem; 2018 Jul; 61(14):6034-6055. PubMed ID: 29939742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
    Chen SF; Perrella FW; Behrens DL; Papp LM
    Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
    Knecht W; Löffler M
    Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
    Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
    Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.